BIOCON:NSE-Biocon Limited (INR)

COMMON STOCK | Biotechnology | NSE

Last Closing Price

INR 282.15

Change

+7.70 (+2.81)%

Market Cap

INR 337.85B

Volume

1.97M

Avg Analyst Target

INR 320.50 (+13.59%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

BIOCON Stock Forecast & Price:
Based on the Biocon Limited stock forecasts from 3 analysts, the average analyst target price for Biocon Limited is INR 320.50 over the next 12 months. Biocon Limited’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Biocon Limited is Slightly Bearish, which is based on 4 positive signals and 8 negative signals. At the last closing, Biocon Limited’s stock price was INR 282.15. Biocon Limited’s stock price has changed by -1.81% over the past week, +3.73% over the past month and -22.17% over the last year.

About Biocon Limited (BIOCON:NSE)

Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology ...Read More

Company Website : https://www.biocon.com

Address : 20th KM, Hosur Road, Bengaluru, India, 560100

Employees : 15,000

Fiscal Year End : March

Currency: INR

Country : India

Technical Indicators

Beta : 0.59

52 Week High : 410.04

52 Week Low : 258.25

200 Day Moving Average : 318.28

50 Day Moving Average : 279.36

Shares Held By Insiders : 65.71%

Shares Held by Institutions : 15.19%

Dividend Yield : 0.17%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SYNGENE:NSE Syngene International Limited

-1.00 (-0.16%)

 INR240.14B 56.17 26.56
PPLPHARMA:NSE Piramal Pharma Limited

+0.95 (+0.72%)

 INR154.16B N/A N/A
JUBLINGREA:NSE Jubilant Ingrevia Limited

+7.10 (+1.33%)

 INR85.99B 23.85 13.65
SUPRIYA:NSE Supriya Lifescience Limited

+3.30 (+1.37%)

 INR19.37B 11.83 9.04
DCAL:NSE Dishman Carbogen Amcis Limited

-0.10 (-0.10%)

 INR15.51B 253.59 9.58
PANACEABIO:NSE Panacea Biotec Limited

+0.30 (+0.22%)

 INR8.45B 0.78 0.20
ZOTA:NSE Zota Health Care LImited

-0.10 (-0.04%)

 INR6.58B 139.07 52.52
LYKALABS:NSE Lyka Labs Limited

+8.85 (+6.95%)

 INR3.57B 17.92 6.58
TAKE:NSE Take Solutions Limited

+0.20 (+0.85%)

 INR3.51B 4.82 -48.65
SMSLIFE:NSE SMS Lifesciences India Limited

+2.35 (+0.36%)

 INR1.87B 7.58 5.40

ETFs Containing BIOCON

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.62% 67% D+ 27% F
Dividend Return 0.14% 50% F 6% F
Total Return -22.49% 67% D+ 26% F
Trailing 12 Months  
Capital Gain -22.23% 67% D+ 19% F
Dividend Return 0.14% 50% F 5% F
Total Return -22.09% 67% D+ 18% F
Trailing 5 Years  
Capital Gain 36.09% 63% D 61% D-
Dividend Return 0.72% 67% D+ 10% F
Total Return 36.81% 63% D 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 6.63% 60% D- 33% F
Dividend Return 0.08% 50% F 9% F
Total Return 6.71% 60% D- 31% F
Risk Return Profile  
Volatility (Standard Deviation) 32.09% 70% C- 80% B-
Risk Adjusted Return 20.91% 60% D- 37% F
Market Capitalization 337.85B 100% A+ 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 54.53 36% F 18% F
Price/Book Ratio 3.52 45% F 33% F
Price / Cash Flow Ratio 28.71 36% F 26% F
EV/EBITDA 17.82 27% F 30% F
Management Effectiveness  
Return on Equity 7.65% 58% F 38% F
Return on Invested Capital 2.98% 45% F 32% F
Return on Assets 3.44% 58% F 43% F
Debt to Equity Ratio 47.42% 33% F 23% F
Technical Ratios  
Dividend Yield 0.17% 38% F 9% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.59 78% C+ 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector